2-(4-(4-Chloro-1-oxo-butyl))-phenyl-2-methylpropanol | 169280-25-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(4-(4-Chloro-1-oxo-butyl))-phenyl-2-methylpropanol
• 英文别名: 2-[4-(4-chloro-butyryl)phenyl]-2-methyl-propanol；4-Chloro-1-[4-(1-hydroxy-2-methylpropan-2-yl)phenyl]butan-1-one
• CAS: 169280-25-5
• 化学式: C₁₄H₁₉ClO₂
• 分子量: 254.757
• InChiKey: HTDDZLNYCILZCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-(4-Chloro-1-oxo-butyl))-phenyl-2-methylpropanol 在 sodium hydroxide 、 四丁基氢氧化铵 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 48.0h， 以96%的产率得到2-(4-(1-Oxo-1-cyclopropanyl)-phenyl)-2-methylpropanol
  参考文献：
  名称：

  Intermediates useful for the preparation of antihistaminic piperidine derivatives

  摘要：

  本发明涉及一种新型中间体和过程，该中间体和过程在制备某些抗组胺酸哌啶衍生物的过程中非常有用，其化学式为 其中 W代表—C(═O)—或—CH(OH)—; R1代表氢或羟基; R2代表氢; R1和R2一起形成连接R1和R2的碳原子之间的第二键; n为1至5的整数; m为0或1的整数; R3为—COOH或—COO烷基，其中烷基基团具有1至6个碳原子，直链或支链，A的每个是氢或羟基;以及其药用可接受盐和各自的光学异构体， 但是当R1和R2一起形成连接R1和R2的碳原子之间的第二键或当R1代表羟基时，m为0。

  公开号：

  US06348597B2
• 作为产物：
  描述：

  4-[4-氯-1-丁酰基]-A,A-二甲基苯乙酸甲酯 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 24.0h， 生成 2-(4-(4-Chloro-1-oxo-butyl))-phenyl-2-methylpropanol
  参考文献：
  名称：

  [EN] FEXOFENADINE POLYMORPHS AND PROCESSES OF PREPARING THE SAME
  [FR] POLYMORPHES DE LA FEXOFENADINE ET LEURS PROCEDES DE PREPARATION

  摘要：

  无水结晶盐酸费索菲丹C型、结晶乙酸费索菲丹单水合物D型、结晶乙酸费索菲丹二水合物E型和结晶费索菲丹游离碱单水合物F型，其制备方法、药物组合物、治疗用途及治疗方法。

  公开号：

  WO2005019175A1

文献信息

• Intermediates useful for the preparation of antihistaminic piperidine
  申请人：Merrell Pharmaceuticals Inc.

  公开号：US06147216A1

  公开（公告）日：2000-11-14

  The present invention is related to a novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of the formula ##STR1## wherein W represents --C(.dbd.O)-- or --CH(OH)--; R.sub.1 represents hydrogen or hydroxy; R.sub.2 represents hydrogen; R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; n is an integer of from 1 to 5; m is an integer 0 or 1; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched each of A is hydrogen or hydroxy; and pharmaceutically acceptable salts and individual optical isomers thereof, with the proviso that where R.sub.1 and R.sub.2 are ta to form a second bond between the carbon R.sub.1 and R.sub.2 or where R.sub.1 represented hydroxy integer 0.

  本发明涉及一种新型中间体和工艺，可用于制备某些抗组胺酸哌啶衍生物，其化学式为##STR1##其中W代表--C(.dbd.O)--或--CH(OH)--；R.sub.1代表氢或羟基；R.sub.2代表氢；R.sub.1和R.sub.2共同形成连接R.sub.1和R.sub.2的碳原子之间的第二键；n为1至5的整数；m为0或1的整数；R.sub.3为--COOH或--COOalkyl，其中alkyl基含有1至6个碳原子，是直链或支链；每个A都是氢或羟基；以及其药用盐和单体光学异构体，但其中R.sub.1和R.sub.2形成连接R.sub.1和R.sub.2的碳原子之间的第二键或R.sub.1代表羟基时除外。
• Intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives
  申请人：Aventisub II Inc.

  公开号：EP2261208A1

  公开（公告）日：2010-12-15

  The present invention is related to novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of formula (I) wherein W represents -C(=O)- or -CH(OH)-; R1 represents hydrogen or hydroxy; R2 represents hydrogen; R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; n is an integer of from 1 to 5; m is an integer 0 or 1; R3 is -COOH or -COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A is hydrogen or hydroxy; and pharmaceutically acceptable salts and individual optical isomers thereof, with the proviso that where R1 and R2 are taken together to form a second bond between the carbon atoms bearing R1 and R2 or where R1 represented hydroxy, m is an integer 0.

  本发明涉及一种新型中间体和制备某些抗组胺哌啶衍生物的方法，其化学式为(I)，其中W代表-C（=O）-或-CH（OH）-；R1代表氢或羟基；R2代表氢；R1和R2一起形成连接带有R1和R2的碳原子之间的第二个键；n为1至5的整数；m为0或1的整数；R3为-COOH或-COOalkyl，其中烷基具有1至6个碳原子，是直链或支链；每个A是氢或羟基；以及其药学上可接受的盐和单一光学异构体，但当R1和R2一起形成连接带有R1和R2的碳原子之间的第二个键或当R1代表羟基时，m为0。
• Process for the preparation of antihistaminic 4-diphenylmethyl piperidine derivatives
  申请人：Aventis Inc.

  公开号：EP1953142A1

  公开（公告）日：2008-08-06

  The present invention is related to novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of formula (I) wherein W represents -C(=O)- or -CH(OH)-; R1 represents hydrogen or hydroxy; R2 represents hydrogen; R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; n is an integer of from 1 to 5; m is an integer 0 or 1; R3 is -COOH or -COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A is hydrogen or hydroxy; and pharmaceutically acceptable salts and individual optical isomers thereof, with the proviso that where R1 and R2 are taken together to form a second bond between the carbon atoms bearing R1 and R2 or where R1 represented hydroxy, m is an integer 0.

  本发明涉及一种新的中间体和过程，可用于制备某些抗组胺哌啶衍生物，该衍生物的化学式为(I)，其中W代表-C(=O)-或-CH(OH)-; R1代表氢或羟基; R2代表氢; R1和R2在承载R1和R2的碳原子之间形成第二个键; n是1到5的整数; m是0或1的整数; R3是-COOH或-COOalkyl，其中烷基具有1到6个碳原子，且为直链或支链; A的每个代表氢或羟基; 以及其药学上可接受的盐和单一光学异构体，但其中当R1和R2在承载R1和R2的碳原子之间形成第二个键或R1代表羟基时，m为0。
• Novel intermediates useful for the preparation of antihistaminic piperidine derivatives
  申请人：Merrell Pharmaceuticals Inc.

  公开号：US20010018521A1

  公开（公告）日：2001-08-30

  The present invention is related to a novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of the formula 1 wherein W represents —C(═O)— or —CH(OH)—; R 1 represents hydrogen or hydroxy; R 2 represents hydrogen; R 1 and R 2 taken together form a second bond between the carbon atoms bearing R 1 and R 2 ; n is an integer of from 1 to 5; m is an integer 0 or 1; R 3 is —COOH or —COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched each of A is hydrogen or hydroxy; and pharmaceutically acceptable salts and individual optical isomers thereof, with the proviso that where R 1 and R 2 are ta′ to form a second bond between the carbon and R 1 and R 2 or where R 1 represented hydroxy integer 0.

  本发明涉及一种新型中间体和过程，其在制备某些抗组胺哌啶衍生物的过程中有用，该衍生物的化学式为1，其中W代表—C(═O)—或—CH(OH)—；R1代表氢或羟基；R2代表氢；R1和R2一起形成连接R1和R2的碳原子之间的第二个键；n为1至5的整数；m为0或1的整数；R3为—COOH或—COO烷基，其中烷基部分具有1至6个碳原子，是直链或支链；每个A都是氢或羟基；以及其药学上可接受的盐和各自的光学异构体，但其中当R1和R2结合形成连接R1和R2的第二个键时，或当R1代表羟基时，n为0。
• Fexofenadine Polymorphs and Processes of Preparing the Same
  申请人：RAO Dharmaraj Ramachandra

  公开号：US20090221830A1

  公开（公告）日：2009-09-03

  Anhydrous crystalline fexofenadine hydrochloride Form C, crystalline fexofenadine acetate monohydrate Form D, crystalline fexofenadine acetate dihydrate Form E and crystalline fexofenadine free base monohydrate Form F, processes of preparing the same, pharmaceutical compositions thereof, therapeutic uses thereof and methods of treatment therewith.

  无水结晶盐酸费索菲尼C型，结晶乙酸费索菲尼单水合物D型，结晶乙酸费索菲尼二水合物E型和结晶费索菲尼游离基单水合物F型，制备上述物质的方法，其制药组合物，治疗用途以及治疗方法。